Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • RESEARCH HIGHLIGHT

How a potent immune therapy loses its punch against a blood cancer

Therapeutic T cells used to treat acute myeloid leukaemia secrete proteins that impair the cells’ own ability to attack cancer.
Light micrograph of bone marrow from a patient with acute myeloid leukaemia, shown in various shades of pink. colours

Bone marrow from a person with acute myeloid leukaemia, a blood cancer that evades treatment with CAR-T-cell therapy. Credit: CNRI/Science Photo Library

The aggressive cancer called acute myeloid leukemia (AML) causes the body to make large numbers of abnormal white blood cells. Researchers have now discovered why a type of immune therapy that can successfully treat other blood cancers is less effective for AML1.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

doi: https://doi.org/10.1038/d41586-024-03141-7

References

  1. Bhagwat, A. S. et al. Nature Med. https://doi.org/10.1038/s41591-024-03271-5 (2024).

    Article  Google Scholar 

Download references

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links